Jacobs Levy Equity Management, Inc Erasca, Inc. Transaction History

Jacobs Levy Equity Management, Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.79 - $2.63 $580,403 - $852,772	324,248 New	324,248 $765,000
Q4 2023 Feb 14, 2024	BUY	$1.67 - $2.49 $1.05 Million - $1.57 Million	629,282 New	629,282 $1.34 Million
Q2 2023 Aug 14, 2023	SELL	$2.57 - $3.3 $363,773 - $467,101	-141,546 Reduced 50.96%	136,201 $375,000
Q1 2023 May 15, 2023	BUY	$2.74 - $4.44 $761,026 - $1.23 Million	277,747 New	277,747 $836,000

140

229M

28.7K

117K

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $336M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.